Financial Results, Dividend Declarations, and Earnings Release Schedules - Analyst Notes on Gilead, Pfizer, Mallinckrodt, Intuitive Surgical and Chicago Bridge & Iron
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, April 29, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Gilead Sciences Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), Mallinckrodt Plc (NYSE: MNK), Intuitive Surgical, Inc. (NASDAQ: ISRG) and Chicago Bridge & Iron Company N.V. (NYSE: CBI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1809-100free.
Gilead Sciences Inc. Analyst Notes
On April 22, 2014, Gilead Sciences, Inc. (Gilead Sciences) announced its results of operations for Q1 2014. The Company's total revenues during the quarter doubled to $5.0 billion from $2.5 billion in Q1 2013, helped mainly by the sales of Sovaldi, which was launched in December 2013, as well as higher sales of Stribild and Complera/Eviplera. Net income for Q1 2014 was $2.2 billion, or $1.33 per diluted share, compared to $722.2 million, or $0.43 per diluted share, in Q1 2013. Adjusted net income during the quarter was $1.48 per diluted share, which far outpaced Reuters' analyst consensus estimates of $0.89. Excluding the impact of Sovaldi product sales, the Company reiterated expectations of full-year 2014 diluted EPS to range between $0.63 and $0.66. The full analyst notes on Gilead are available to download free of charge at:
http://www.analystsreview.com/1809-GILD-29Apr2014.pdf
Pfizer Inc. Analyst Notes
On April 24, 2014, Pfizer Inc. (Pfizer) announced that its Board of Directors has declared a cash dividend of $0.26 per common stock for Q2 2014, payable June 3, 2014, to shareholders of record at the close of business on May 9, 2014. The Q2 2014 cash dividend will be the 302nd consecutive quarterly dividend paid by Pfizer. Ian Read, Chairman and CEO, commented, "We returned almost $23 billion to shareholders in 2013 through dividends and share repurchases. In 2014, we are continuing to take actions to increase shareholder value, including our dividend increase announced in December 2013 and our continued shares repurchase activity." The full analyst notes on Pfizer are available to download free of charge at:
http://www.analystsreview.com/1809-PFE-29Apr2014.pdf
Mallinckrodt Plc Analyst Notes
On April 21, 2014, Mallinckrodt Plc (Mallinckrodt) announced that it will report its Q2 FY 2014 results on Thursday, May 8, 2014 and will hold a conference call for investors from 7:30 - 8:00 am, U.S. ET. According to Zacks Investment Research, the consensus EPS estimate for the quarter is $0.78. The adjusted diluted earnings per share in Q1 FY 2014 stood at $0.88. Mallinckrodt's net sales were $540.2 million in Q1 FY 2014, up 7.2%, compared with $504.0 million in Q1 FY 2013. The Company recently agreed to acquire Questcor Pharmaceuticals, Inc. for approximately $5.6 billion, as part of the plan to increase focus on the specialty pharmaceuticals business. The full analyst notes on Mallinckrodt are available to download free of charge at:
http://www.analystsreview.com/1809-MNK-29Apr2014.pdf
Intuitive Surgical, Inc. Analyst Notes
On April 22, 2014, Intuitive Surgical Inc. (Intuitive Surgical) reported Q1 2014 financial results. The Company's revenues during the quarter fell 24.0% YoY to $464.7 million, weighed down mainly by sharp decline in Systems revenues. Systems revenue dropped to $106 million from $255.9 million in Q1 2013, as number of da Vinci surgical systems shipped fell sharply (87 in Q1 2014 as compared to 164 in Q1 2013). U.S. system shipments were down in the first quarter of 2014 as a result of lower procedure growth, changing hospital capital spending priorities associated with the implementation of the affordable Care Act, and the impact that anticipation of a new system may have had on customer capital-spending decisions, said the Company in a statement. The Company's net income during the quarter was $44.3 million, or $1.13 per diluted share, compared to $188.9 million, or $4.56 per diluted share, in Q1 2013. The full analyst notes on Intuitive Surgical are available to download free of charge at:
http://www.analystsreview.com/1809-ISRG-29Apr2014.pdf
Chicago Bridge & Iron Company N.V. Analyst Notes
On April 23, 2014, Chicago Bridge & Iron Company N.V. (CB&I) released its Q1 2014 financial results. The Company's net income during the quarter was $ 89.0 million, or $0.82 per share, compared to $33.6 million, or $0.32 per share, in Q1 2013. The Company's adjusted net income for the quarter came in at $94.4 million, or $0.87 per diluted share, missing the Reuters' analyst consensus estimate of $1.10. CB&I's revenues were up by 30.1% YoY at $2.9 billion. Q1 2014 new awards totaled $5.8 billion, resulting in a backlog of $30.7 billion. "These awards are diverse in size, value and geography and reflect our ability to continue to capitalize on our global end markets across each of our operating groups," said Philip K. Asherman, President and CEO. The stock fell to $82.19 on April 24, 2014, reflecting a decline of 5.17% from previous day's close. The full analyst notes on ChicagoBridge & Iron are available to download free of charge at:
http://www.analystsreview.com/1809-CBI-29Apr2014.pdf
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
Share this article